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ABSTRACT 
The objective of the present study was to prepare immediate release tablets (IRTs) of valsartan by direct compression method. Two types of 
superdisintegrants i.e. sodium starch glycolate (SSG) and Ac-Di-sol were used in the formulation of tablets. Twelve preliminary trial batches 
were prepared by varying the concentration of superdisintegrants. It was found that formulation containing Ac-Di-Sol disintegrated in less time 
as compared to formulation containing sodium starch glycolate. Values of friability was found to be more in case of formulation containing Ac-Di-
Sol. Attempts were also made to prepare the tablets containing superdisintegrants in combination and these resulted in the formulation with 
improved values of disintegration time and friability. On the basis of preliminary studies optimization of IRT was done employing 32 full factorial 
design using design expert 7. The optimized batch of IRTs showed friability and disintegration time values of 0.82 ± 0.07 and 29 ± 1 respectively. 
The percent release was also found to be 94.73 ± 4.97% in 5 min. 
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INTRODUCTION 
Oral administration is the most popular route for systemic 
effects due to its ease of ingestion, pain, avoidance, 
versatility and most importantly, patient compliance. Also, 
solid oral delivery systems do not require sterile conditions 
and are therefore, less expensive to manufacture. Patient 
compliance, high precision dosing, and manufacturing 
efficiency make tablets the solid dosage form of choice. In 
present study IRTs were formulated that disintegrate in less 
time delivering fine suspension of particles of drug with 
large surface area, resulting in increased rate of dissolution1.  
In the present study, Valsartan was selected as the model 
drug. Valsartan blocks the actions of angiotensin II, which 
include constricting blood vessels and activating 
aldosterone, to reduce blood pressure. The drug binds to 
angiotensin type I receptors (AT1), working as an antagonist. 
This mechanism of action is different than the ACE inhibitor 
drugs, which block the conversion of angiotensin I to 
angiotensin II. Since valsartan acts at the receptor, it can 
provide more complete angiotensin II antagonism since 
angiotensin II is generated by other enzymes as well as ACE. 
Also, valsartan does not affect the metabolism of bradykinin 
like ACE inhibitors do.2 
In the formulation of immediate release tablets basic 
approach is to use superdisintegrants. In the present study 
two types of superdisintegrants (sodium starch glycolate and 
Ac-Di-Sol) were used. Concentration of both 
superdisintegrants was optimized by employing 32 full 
factorial design. 
MATERIALS AND METHOD 
Materials 
Valsartan and Avicel pH101 was obtained from Zydus 
Cadilla, Ahmedabad. Sodium starch glycolate, talc and 
magnesium stearate were obtained from Nice Chemicals Pvt. 
Ltd. Kerala, India. Ac-Di-Sol was obtained from Optica 
Pharmaceuticals, Haryana, India. 
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Methods 
Preparation of immediate release tablets 
The complete set of ingredients (Table no. 1) including the 
drug and excipients were passed through sieve no 20. 
Valsartan, sodium starch glycolate, Ac-Di-Sol and Avicel PH-
101 were blended using a mortar and pestle. Into this the 
measured quantity of talc and magnesium stearate were 
added. This blend was compressed using a 6.0-mm tooling 
punch on a single punch tablet machine. 
 
Table 1: Composition of preliminary trial batches of immediate release tablets 
Ingredients (mg) 
   Formulation Code 
CT1 CT2 CT3 CT4 CT5 CT6 CT7 CT8 CT9 CT10 CT11 CT12 
Valsartan 80 80 80 80 80 80 80 80 80 80 80 80 
Ac-di-sol 2 4 6 8 - - - - 2 4 6 8 
Sodium starch glycolate - - - - 2 4 6 8 2 4 6 8 
Avicel PH 101 64 62 60 58 64 62 60 58 62 58 54 50 
Magnesium Stearate  2 2 2 2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 2 2 2 
 
Evaluation 
The prepared immediate release tablets were evaluated for 
weight variation and thickness. Using micrometer thickness 
was determined for twenty tablets3. Weight variation of 
prepared tablets was determined as per USP4 by taking 
twenty tablets and comparing average weight with the 
individual weight of tablets. Hardness of ten tablets5 from 
each batch was determined using pfizer hardness tester and 
Friability of all batches of IRT was determined as per USP6 
using Roche friabilator. Sample of whole tablets 
corresponding to about 6.5 g was placed in the friabilator 
and were subjected to 100 revolutions. 
The prepared IRTs were subjected to assessment of in-vitro 
disintegration time using USP-27/NF-22 disintegration test 
apparatus7. Drug content of prepared IRTs were carried out 
by crushing ten tablets in a glass mortar and transferred 
quantitatively with methanol in a stoppered conical flask. 
The flask was placed in a sonicator for 30 min. The mixture 
was filtered and an aliquot, following suitable dilution, was 
analyzed at 248 nm using a UV spectrophotometer8.  
In vitro release study 
The dissolution studies of prepared IRTs were carried out 
using USP type II dissolution test apparatus9.The paddle 
rotation speed and temperature were set to 100 rpm and 
37±0.5°C respectively. The dissolution medium was 900 ml 
of the 0.1N HCl of pH 1.2. At particular time intervals 5 ml 
sample was withdrawn and analysed in UV 
spectrophotometer at 248 nm. Samples were collected 
periodically at different time intervals (1,2,3,4 and 5min) 
and replaced with fresh dissolution medium. The absorbance 
was determined spectrophotometrically at 248 nm. 
Dissolution profiles were constructed as shown in Fig 1. 
Concentrations were calculated using calibration curves 
developed in respective media. 
Experimental design 
To know the actual amount of polymers for the desirable 
property of tablets a 32 randomized full factorial design was 
used. Combination of these trials is represented in table 2. 
Nine formulations (Table 3) were prepared according to 
experimental design. In this design 2 factors are evaluated, 
each at 3 levels and experimental trials are performed at all 
9 possible combinations. The amount of Ac-di-sol (X1) and 
the amount of Sodium starch glycolate (X2) was selected as 
independent variables. The amount of polymers was varied 
from 2,4 and 6mg. The friability and disintegration time 
were selected as dependent variables.  
 
Table 2: Experimental plan of 32 full factorial design 
F. Code SSG Concentration (X1) Ac-Di-Sol Concentration (X2) 
ECT1 -1 -1 
ECT2 0 -1 
ECT3 +1 -1 
ECT4 -1 0 
ECT5 0 0 
ECT6 +1 0 
ECT7 -1 +1 
ECT8 0 +1 
       ECT9 +1 +1 
 
Table 3: Formulation of experimental batches of Immediate release tablets 
Ingredients (mg) Formulation Code 
 
ECT1 ECT2 ECT3 ECT4 ECT5 ECT6 ECT7 ECT8 ECT9 
Valsartan 80 80 80 80 80 80 80 80 80 
Ac-di-sol 4 6 4 2 4 6 2 6 2 
Sodium starch glycolate 4 2 6 6 2 4 2 6 4 
Avicel PH 101 58 58 56 58 60 56 62 54 60 
Magnesium Stearate 2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 
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A statistical model incorporating interactive and polynomial 
terms was used to evaluate the responses. 
Y = b0 + b1X1 + b2X2 + b11X1X1 + b22X2X2 + b12X1X2 
Where, Y is the dependent variable, b0 is the arithmetic mean 
response of the 9 runs, and b1 is the estimated coefficient for 
the factor X1. The main effects (X1 and X2) represent the 
average result of changing 1 factor at a time from its low to 
high value. The interaction terms (X1X2) show how the 
response changes when 2 factors are simultaneously 
changed. The polynomial terms (X1X1 and X2X2) are included 
to investigate nonlinearity. 10 
Optimization of IRT 
After application of full factorial design and with help of 
polynomial terms the optimized tablet (FRC1) was produced. 
Tablets were prepared as per composition given in table 4. 
This batch targeted to the friability of less then 1% and 
disintegration time of 30 s. The observed response for 
friability and disintegration time were 0.82 ± 0.07 and 
29±1 respectively. 
Table 4: Composition of optimum batch (FRC1) of 
immediate release tablet 
Ingredients FRC1 
Valsartan 80 
Acdisol 4.32 
Sodium starch glycolate 4.36 
Avicel PH 101 67.32 
Magnesium Stearate 2 
Talc 2 
 
Stability studies 
To assess the stability of formulation, the optimum IRTs 
were packed in an amber colored air tight vial and stored 
at (40 ± 2 °C and 75 ± 5% RH) for a period of 6 months. 
The tablets were withdrawn after a particular period of time, 
analyzed for physical appearance, weight, hardness, 
friability, disintegration time, drug content, and % drug 
release. At this point, the data was statistically analyzed 
using ANOVA to test the significance of difference at the level 
of significance. 
RESULTS AND DISCUSSION 
Evaluation of preliminary FDT batches and experimental 
batches   
Preliminary batches of IRT of valsartan were prepared by 
direct compression method employing sodium starch 
glycolate and Ac-Di-Sol as superdisintegrants. Directly 
compressible Avicel PH 101, was used as diluent. A total of 
twelve formulations were designed, in formulation CT1-CT4 
and CT5-CT8 varying concentration of Ac-Di-Sol and sodium 
starch glycolate were incorporated respectively. CT9-CT12 
formulations were prepared, containing both sodium starch 
glycolate and Ac-Di-Sol in different concentrations. Low 
Hausner’s ratio (≤ 1.25), compressibility index (≤ 11.122) 
and angle of repose (≤ 28.33) values indicated a fairly good 
flow ability of powder mixture. All the formulations 
exhibited uniform weight, as per USP5 with low standard 
deviation values, indicating the uniformity of the tablets 
prepared by direct compression method. Average tablet 
thickness was found to be within limits (± 5%) (Banker et al. 
198711 and Beringer et al. 200512). The % friability of all the 
formulations was found to be 0.445–1.253. Results of 
preliminary batch are shown in Table 5. 
 
Table 5: Characterization of preliminary batch of compressed immediate release tablets 
Parameters  Thickness 
(mm)  
Weight 
(mg)  
Hardness 
(kg/cm2)  
Friability 
(% )  
Disintegration 
test 
Drug content 
(%) 
CT1 3.5604±0.004  150.65 ± 2.796 3.33±0.15 0.48±0.047 98.667±3.055 100±0.25  
CT2 3.5603±0.004  150.95 ± 3.649 3.13±0.25 0.776±0.012 91.667±4.163 100±0.47  
CT3 3.2073±0.002  150.95 ± 4.11 3.27±0.06 0.843±0.038 78±4 99±0.32  
CT4 3.728±0.124  150.9 ± 4.376 3.2±0.1 0.934±0.041 67±2 101±0.11  
CT5 3.3258±0.004  150.3 ± 4.473 3.57±0.15 0.445±0.021 126.333±2.517 100±0.23  
CT6 3.454±0.002  150.7 ± 3.496 3.8±0.1 0.574±0.021 116.333±1.528 99±0.45  
CT7  3.6631±0.11  151.45 ± 3.441 3.3±0.2 0.681±0.017 109±2 100±0.13  
CT8 3.2165±0.002  150.45 ± 3.17 3.37±0.21 0.853±0.03 104.333±2.082 101±0.28  
CT9 3.3568±0.004  148.45 ± 5.853 2.9±0.2 0.659±0.018 57.333±2.082 99±0.18  
CT10 3.1603±0.014  151.6 ± 3.068 3.33±0.06 0.894±0.009 35.667±1.528 100±0.13  
CT11  3.4073±0.022  150.05 ± 2.911 3.33±0.25 0.981±0.006 22±1 102±0.29  
CT12  3.5208±0.014  147.95 ± 5.558 3±0.36 1.253±0.041 10±1 100±0.36  
 
On the basis of preliminary studies it was found that with 
increase in concentration of SSG and Ac-Di-Sol tablets 
disintegrated in less time and value of friability increased. 
Disintegration time of tablets containing SSG was more as 
compared to tablets containing Ac-Di-Sol, whereas friability 
value was more in case of tablets containing Ac-Di-Sol. Thus 
based on this study both SSG and Ac-Di-Sol were used 
together for further studies. Drug content of randomly 
selected ten tablets were determined and it was found that 
obtained values were within the limits as per USP. Obtained 
data for experimental batch was found to be between 99.18-
102.29%. 
Statistical and response surface analysis of models 
Statistical analysis 
It was found there was a wide variation in the values of 
disintegration time and friability with change in 
concentration of two factors. Table 6 describes the effect of 
SSG concentrations (2, 4, and 6mg) and Ac-Di-Sol 
concentrations (2,4 and 6mg) on the characteristics of IRT. 
Results showed that with increase in concentration of SSG 
and Ac-Di-Sol disintegration time decreased. The 
formulation (ECT1-ECT9) showed disintegration time 
ranging from 22 to 57. 
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Table 6: Effect of superdisintegrant concentration on the characteristics of the prepared immediate release tablet 
formulations of experimental batch 
Formulation Acdisol (X1) SSG (X2) Disintegration time (sec) Friability (%) 
ECT 1 0.00 0.00 35 0.894 
ECT 2 1.00 -1.00 27 0.934 
ECT 3 0.00 1.00 31 0.921 
ECT 4 -1.00 1.00 47 0.834 
ECT 5 0.00 -1.00 38 0.872 
ECT 6 1.00 0.00 24 0.954 
ECT 7 -1.00 -1.00 57 0.659 
ECT 8 1.00 1.00 22 0.981 
ECT 9 -1.00 0.00 52 0.721 
 
 
Figure 1: Percent released of Valsartan from compressed immediate release tablets. 
 
In case of friability it was found that with increase in 
concentration of SSG and Ac-Di-Sol friability value of IRTs 
also increased. 
The in vitro drug release data of prepared IRTs is depicted 
graphically in fig.1. According to the dissolution profile it was 
found that all batches released drug within 5 min. 
Percentage of drug released from all the formulation varied 
between 94.471-98.08% within 5 min. 
Optimization 
Optimization was done employing a 32 FFD. The 
dependent and independent variables were related using 
quadratic equations obtained with the Design Expert 
software (Version 7). ANOVA was performed to identify 
insignificant factors. Model selection was based on lower p 
values than assigned significance level, high F value, absence 
of lack of fit, highest level of adjusted R2 and predicted 
R2, low standard deviation and lower press value. All values 
are represented in Table 7. F-value of 49.464 in case of 
friability and 646.01 in case of disintegration time, implies 
the model is significant. High values of R2 for all dependent 
variables were obtained, which indicate a good fit. Adj-R2 
and Pred-R2 values for all responses were in reasonable 
agreement, signifying good model fit. Further, the adequate 
precision value greater than four indicated adequate model 
discrimination. Values of p less than 0.05 indicated that 
model terms are significant. 
 
 
Table 7: ANOVA results of full and reduced model for immediate release tablets 
  Std. Dev. R-Squared Sum of squares Mean of squares F Value p-value Prob > F 
DT 0.624404478 0.998763166 1259.340476 251.8680952 646.0128244 < 0.0001 
FRIABILITY 0.0194194 0.984084042 0.093267648 0.01865353 49.46401957 0.0011 
 
Response surface analysis 
Response surface plots were generated for each response to 
study the behavior of the system. Response surface plot for 
friability in (Fig. 2) shows that with the increase in 
the concentration of SSG and Ac-Di-Sol the friability value of 
the tablet also increases in a linear manner. In case 
of disintegration time Response surface plot (Fig. 3) 
shows that with the increase in the concentration of SSG and 
Ac-Di-Sol the disintegration time decreased in a linear 
manner.
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Figure 2: Response surface graph showing the influence of X1 and X2 on the friability of immediate release tablets of 
Valsartan 
 
Figure 3: Response surface graph showing the influence of X1 and   X2 on the disintegration time of immediate release 
tablet of Valsartan 
Stability studies 
Accelerated stability studies on the optimized promising 
formulation were carried out by storing the tablet at 40 ± 2 
°C and 75 ± 5% RH for 6 months. At regular intervals, the 
formulation was characterized for weight, hardness, 
disintegration time, friability and drug content. It is found 
that there was no change in physical appearance, and other 
tablet characteristics during the study period and at the end 
of the 6 months. Also, no significant change was shown in the 
percent drug release. Thus, results imply good stability of the 
formulation on 6-month storage. 
CONCLUSION 
It can be concluded from the present study that using 
appropriate concentration of Superdisintegrants SSG and Ac-
Di-Sol IRT can be formulated with acceptable values of 
disintegration time and friability. Addition of super 
disintegrating agent resulted in development of a 
formulation with lesser disintegration time. It was also found 
that above 90% of drug was released within 5 min. due to 
quick disintegration of the tablet. Thus, the present 
investigation concluded that it is possible to formulate IRT 
with acceptable physical characteristics having less 
disintegration time and could be used to provide immediate 
relief in hypertension. 
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